Novavax announces second quarter 2026 financial results
The company highlights continued progress on its corporate growth strategy and hosts a live earnings call at 8:30 a.m. ET.
See the latest news and media coverage for Novavax. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biotechnology company developing vaccines
novavax.comLast updated
In short: Novavax reported Q2 2026 revenue of $57 million and raised its full-year guidance as it pivoted toward technology licensing partnerships.
The company highlights continued progress on its corporate growth strategy and hosts a live earnings call at 8:30 a.m. ET.
Total revenue declined 76% to $57 million, net loss $53 million. Raised full-year revenue guidance and reduced expense guidance. Sanofi partnership and C. difficile program highlighted.
The strategy uses Matrix-M adjuvant and nanoparticle technology to generate partner data and pipeline assets.
They highlight progress on corporate growth strategy and invite to a live call at 8:30 a.m. ET.
Reported total revenue of $57 million for the second quarter of 2026 and raised full-year 2026 Revenue Framework Improved GAAP Combined R&D and SG&A expense...
Novavax (NVAX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...
Shares of Novavax Inc NVAX are trading higher Tuesday. The stock is up over 30% over the trailing month as traders weigh updated autumn vaccine...
Novavax said Sanofi and Takeda received clearances for an updated Nuvaxovid formulation for the...
Track Novavax and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Novavax and other trending companies.